Treatment and prognosis of multifocal osteosarcoma：6 cases report

ZHANG Zeng-liang; LI Nan; CHEN Bing-yao; SONG Guang-ze; WANG Shuo; WEI Xing

doi:10.3969/j.issn.2095-252X.2015.08.008

Abstract：Objective To investigate the curative outcomes and prognosis of multifocal osteosarcoma ( MFOS ).Methods From March 2010 to December 2014, 6 patients with MFOS were adopted, including 4 males and 2 females. Four patients ( A1, A2, A3 and A4 ) were diagnosed as synchronous MFOS at the ifrst visit. Metachronous MFOS was noticed in the other 2 patients ( B1 and B2 ) during the treatment process. Neoadjuvant chemotherapy was performed preoperatively and chemotherapy postoperatively. One of the 6 patients gave up, and the other 5 patients received chemotherapy and surgery. Surgery was performed on 4 patients after 1-2 cycles of chemotherapy. The chemotherapy drugs used in these patients for each cycle included adriamycin ( 60 mg / m2 ) at the 1-2 day, cisplatinum ( 100 mg / m2 ) at the 3 day, methopterin ( 8-12 g / m2 ) and vincristine ( 1.4 mg / m2 ) at the 14 day and ifosfamide ( 12.5 g / m2 ) at the 21-25 day, once a day. The interval time was 3 weeks between the 1st and 2nd round of chemotherapy. Results The patient ( A1 ) who gave up the treatment died 5 months after the diagnosis. One patient ( A4 ) survived for nearly 4 months after the diagnosis, and was still under treatment. The survival time of the other 4 patients ( A2, A3, B1 and B2 ) was 19, 6, 13 and 18 months respectively.Conclusions The prognosis of the patients with MFOS is poor. To improve the prognosis of the patients with MFOS, aggressive chemotherapy and surgery are needed.